First of all, 2C-X-NBOMe's doesn't seem to tolerate too many changes to their structure. DOX's drugs don't really benefit from adding NBOMe part as 2C-X's do. So you really need to be careful when you add bulk to a compound's structure.
Also, cyclohexane has completely different chemical properties from benzene. In benzene there is a lot going there, because you've got a delocalized pi system there, so its electrons are capable of creating interaction based on charges and partial charges, especially when it's also substituted. E.g. that's how dopamine interacts with DAT, its 3,4-dihydroxyphenyl part interacts with the same site as the ester part in cocaine and phenyltropanes. And that's also how, I think, the analogues of NBOMe's that I posted yesterday would substitute for LSD/LSZ and 2C-X-NBOMe's. Of course when you change one functional group to another, you have to remember that it may not have exactly the same properties even if it has the same size.
In your compound, you don't have a secondary amine there. You've got a dioxazepanone fused into the ethyl side-chain, too many oxygens there and that nitrogen won't be able to interact in the way amines in 2C-X's and 2C-X-NBOMe's interact with the 5-HT(2A) receptors. Perhaps it would be metabolised into some amount of 2C-B, but that's just about it. The 4-methylcyclohexyl part (the one that you mistook for phenyl, I guess) certainly won't substitute for 2-methoxybenzyl in NBOMe's. Generally I don't think that your original compound would be stable, also, I don't really think that it would pay off to synthesize it. But above all I think that your molecule is too big to fit in as NBOMe's fit into the receptor's cleft.